PMID- 10704947
OWN - NLM
STAT- MEDLINE
DCOM- 20000404
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 59
IP  - 9
DP  - 2000 May 1
TI  - Stimulation of 90- and 70-kDa ribosomal protein S6 kinases by arginine 
      vasopressin and lysophosphatidic acid in rat cardiomyocytes.
PG  - 1163-71
AB  - Arginine vasopressin (AVP) and lysophosphatidic acid (LPA) have been shown to 
      stimulate protein kinase C (PKC) and mitogen-activated protein (MAP) kinases and 
      the proliferation of vascular smooth muscle cells. However, the actions of these 
      two agents in cardiomyocytes are less well understood. To investigate the signal 
      transduction pathways of AVP and LPA, freshly isolated adult rat cardiomyocytes 
      were examined. Both AVP and LPA induced concentration- and time-dependent 
      stimulation of the phosphotransferase activities of p90 ribosomal S6 kinases 
      (RSK) and their upstream activators, extracellularly regulated kinases (ERK) 1 
      and 2. The activation of ERK1 and ERK2 by LPA was PKC- and phosphatidylinositol 
      3-kinase (PI 3-kinase)-dependent. However, AVP-induced activation of RSK2, a 
      downstream substrate of ERK1 and ERK2, was PKC-dependent and PI 
      3-kinase-independent. AVP and LPA were also observed to increase the 
      phosphotransferase activity of p70 ribosomal protein S6 kinase (p70 S6K) in a 
      time- and concentration-dependent manner. The activation of p70 S6K by LPA and 
      AVP was PI 3-kinase-dependent. PKC was necessary in AVP- but not in LPA-induced 
      activation of p70 S6K. Since RSK and p70 S6K have been implicated in the 
      regulation of translational control of protein synthesis, we concluded that AVP 
      and LPA may stimulate the growth of cardiomyocytes through these two protein 
      kinase cascades.
FAU - Xu, Y J
AU  - Xu YJ
AD  - Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
FAU - Ouk Kim, S
AU  - Ouk Kim S
FAU - Liao, D F
AU  - Liao DF
FAU - Katz, S
AU  - Katz S
FAU - Pelech, S L
AU  - Pelech SL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Lysophospholipids)
RN  - 113-79-1 (Arginine Vasopressin)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Animals
MH  - Arginine Vasopressin/*pharmacology
MH  - Enzyme Activation/drug effects
MH  - Heart/*drug effects
MH  - In Vitro Techniques
MH  - Lysophospholipids/*pharmacology
MH  - Male
MH  - Mitogen-Activated Protein Kinase 1/metabolism
MH  - Mitogen-Activated Protein Kinase 3
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Molecular Weight
MH  - Myocardium/*enzymology/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Ribosomal Protein S6 Kinases/drug effects/*metabolism
EDAT- 2000/03/08 00:00
MHDA- 2000/03/08 00:01
CRDT- 2000/03/08 00:00
PHST- 2000/03/08 00:00 [pubmed]
PHST- 2000/03/08 00:01 [medline]
PHST- 2000/03/08 00:00 [entrez]
AID - S0006-2952(00)00239-2 [pii]
AID - 10.1016/s0006-2952(00)00239-2 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2000 May 1;59(9):1163-71. doi: 10.1016/s0006-2952(00)00239-2.